Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

25 juin 2019 14h01 HE | Source: ImmusanT, Inc.

ImmusanT Discontinues Phase 2 Clinical Trial for Nexvax2® in Patients With Celiac Disease

CAMBRIDGE, Mass., June 25, 2019 (GLOBE NEWSWIRE) -- ImmusanT, Inc., a clinical stage company leveraging its Epitope-Specific Immuno-Therapy™ (ESIT™) platform to deliver first-in-class peptide-based...
29 mai 2019 10h17 HE | Source: ImmusanT, Inc.

ImmusanT to Present at the Jefferies 2019 Healthcare Conference

CAMBRIDGE, Mass., May 29, 2019 (GLOBE NEWSWIRE) -- ImmusanT, Inc., a clinical stage company leveraging its Epitope-Specific Immuno-Therapy™ (ESIT™) platform to deliver first-in-class peptide-based...
21 mai 2019 12h12 HE | Source: ImmusanT, Inc.

ImmusanT Presents Early Evidence Supporting its Lead Therapeutic Vaccine Candidate During the Digestive Disease Week Annual Conference 2019

CAMBRIDGE, Mass., May 21, 2019 (GLOBE NEWSWIRE) -- ImmusanT, Inc., a clinical stage company leveraging its Epitope-Specific Immuno-Therapy™ (ESIT™) platform to deliver first-in-class peptide-based...
16 mai 2019 10h35 HE | Source: ImmusanT, Inc.

ImmusanT to Present New Findings on Celiac Disease and Lead Therapeutic Candidate During the Digestive Disease Week Annual Conference 2019

CAMBRIDGE, Mass., May 16, 2019 (GLOBE NEWSWIRE) -- ImmusanT, Inc., a clinical stage company leveraging its Epitope-Specific Immuno-Therapy™ (ESIT™) platform to deliver first-in-class peptide-based...
21 mars 2019 13h00 HE | Source: ImmusanT, Inc.

ImmusanT to Present and Participate in Multiple Upcoming Industry and Scientific Conferences

ImmusanT CEO Leslie Williams to speak on panel during the MassBio Annual “The State of Possible Conference” ImmusanT CSO Dr. Bob Anderson to present on Nexvax2 at the 2nd Antigen Specific Immune...
06 mars 2019 08h00 HE | Source: ImmusanT, Inc.

ImmusanT to Provide Corporate Overview at the Cowen & Company 39th Annual Health Care Conference

CAMBRIDGE, Mass., March 06, 2019 (GLOBE NEWSWIRE) -- ImmusanT, Inc., a clinical-stage company leveraging its Epitope-Specific Immuno-Therapy™ (ESIT™) platform to deliver first-in-class peptide-based...
03 janv. 2019 09h47 HE | Source: ImmusanT, Inc.

ImmusanT Expands Senior Management Team with Appointment of Thomas A. Shea as Chief Financial Officer

CAMBRIDGE, Mass., Jan. 03, 2019 (GLOBE NEWSWIRE) -- ImmusanT, Inc., a clinical-stage company leveraging its Epitope-Specific Immuno-Therapy™ (ESIT™) platform to deliver first-in-class peptide-based...
02 janv. 2019 10h17 HE | Source: ImmusanT, Inc.

ImmusanT Secures Fast-Track Designation for Lead Therapeutic Vaccine Candidate Nexvax2 for Patients with Celiac Disease (CeD)

CAMBRIDGE, Mass., Jan. 02, 2019 (GLOBE NEWSWIRE) -- ImmusanT, Inc., a clinical-stage company leveraging its Epitope-Specific Immuno-Therapy™ (ESIT™) platform to deliver first-in-class peptide-based...
07 déc. 2018 12h53 HE | Source: ImmusanT, Inc.

ImmusanT Chief Scientific Officer Robert Anderson, Ph.D. to Participate as a Featured Speaker During the Antigen-Specific Immune Tolerance Europe Conference 2018

CAMBRIDGE, Mass., Dec. 07, 2018 (GLOBE NEWSWIRE) -- ImmusanT, Inc., a clinical stage company leveraging its Epitope-Specific Immuno-Therapy™ (ESIT™) platform to deliver first-in-class peptide-based...
20 nov. 2018 09h30 HE | Source: ImmusanT, Inc.

ImmusanT CEO Leslie Williams to Present at Multiple Life Sciences Events to Share Company’s Leadership Position in the Industry and Successful Growth Strategy

CAMBRIDGE, Mass., Nov. 20, 2018 (GLOBE NEWSWIRE) -- ImmusanT, Inc., a clinical stage company leveraging its Epitope-Specific Immuno-Therapy™ (ESIT™) platform to deliver first-in-class peptide-based...

Page suivante